aap Implantate Announces Rights Issue and Debt-to-Equity Swap
The company plans to issue up to 1,486,563 shares at EUR 1.35 each, with a 9.9-to-1 subscription ratio. It also intends to convert shareholder loans into equity and confirmed its 2026 revenue and EBITDA guidance.
On November 2, 2026, the Management Board of aap Implantate AG, with Supervisory Board approval, announced a capital increase against cash contributions via a rights issue. The company plans to issue up to 1,486,563 new shares at a subscription price of EUR 1.35 per share, with a subscription ratio of 9.9 to 1. Additionally, the company intends to perform a capital increase against contributions in kind to convert shareholder loans into equity, aiming to eliminate loan liabilities and associated interest expenses. These measures are designed to strengthen the company's liquidity position and balance sheet structure.
The subscription period for the rights issue is expected to run from November 6 to November 20, 2026. Furthermore, the company confirmed its full-year 2026 revenue and EBITDA guidance.